Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Anavex Life Sciences Corp.NASDAQ: AVXL
Net Receivables · Q1 FY2026 · quarter ended Dec 2025
Net receivables falls 67.0% from a year ago
Net receivables stood at $844K at the end of Q1 FY2026, down 67.0% from a year earlier and up 4.3% from the prior quarter. Over 3 fiscal years it compounded at -36.7% a year.
Context
- Net receivables amounted to 0.6% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -67.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 809K USD
- Year-over-year change
- -67.0%
- 4-year CAGR
- -45.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 809K | -67.0% |
| FY2024 | 2024-09-30 | 2.45M | -9.6% |
| FY2023 | 2023-09-30 | 2.71M | -15.2% |
| FY2022 | 2022-09-30 | 3.19M | -65.1% |
| FY2021 | 2021-09-30 | 9.14M | — |
Net Receivables vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -67.0% is the 7th highest of 10, against a peer median of -42.9%.
- Net receivables amounts to 0.6% of total assets for AVXL, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $17.96M USD | +243.7% | -14.3% | 7.3% | |
| Mar 2026 | $10.94M USD | -42.9% | -3.3% | 3.2% | |
| Mar 2026 | €10.14M EUR | -69.7% | +5.2% | 2.7% | |
| Mar 2026 | $6.4M USD | -23.8% | -7.2% | 1.0% | |
| Mar 2026 | $5.76M USD | +92.9% | +182.0% | 1.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $3.23M USD | +108.7% | +146.2% | 0.6% |
| Dec 2025 | $844K USD | -67.0% | -36.7% | 0.6% | |
| Mar 2026 | $646K USD | -67.0% | -61.8% | 0.2% | |
| Sep 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding AVXL) | — | -42.9% | -3.3% | 1.0% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 152.11M | 149.16M | 151.02M | 132.19M | 102.58M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 9.14M | 3.19M | 2.71M | 2.45M | 809K |
| Inventory | 16.37K | 0 | 0 | 0 | 0 |
| Other Current Assets | (16.37K) | 162 | 653K | 931K | 429K |
| Total Current Assets | 161.62M | 152.7M | 154.39M | 135.57M | 103.82M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 16.37K | 3.55B | 3.36M | 0 | 0 |
| Total Non-current Assets | 16.37K | 3.55B | 3.36M | 0 | 0 |
| Total Assets | 161.62M | 152.7M | 154.39M | 135.57M | 103.82M |
| Account Payables | 4.74M | 3.82M | 4.32M | 9.63M | 4.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 443.83K | 443.83K | 917K | 842K | 805K |
| Other Current Liabilities | 0 | (47) | 1.36M | 1.53M | 1.56M |
| Total Current Liabilities | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M |
| Common Stock | 75.92K | 77.94K | 82K | 85K | 87K |
| Retained Earnings | (197.59M) | (245.56M) | (293.07M) | (336.07M) | (382.45M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 150.82M | 142.49M | 141.85M | 120.26M | 94.87M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (152.11M) | (149.16M) | (151.02M) | (132.19M) | (102.58M) |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.